J&J Hit With $8 Billion Jury Award Over Antipsychotic Drug: J&J is expected to appeal punitive damages award to a man who alleged Risperdal caused enlarged breasts
This article is behind a paywall. Harvard affiliates can access the full text via Hollis.
A Philadelphia jury on Tuesday ordered Johnson & Johnson to pay $8 billion in damages to a Maryland man who said his use of J&J's antipsychotic Risperdal as a child caused enlarged breasts and the company failed to properly warn of this risk.
It was the biggest award to date among more than 13,000 lawsuits against J&J alleging that Risperdal caused a condition called gynecomastia in boys, which involves enlargement of breast tissue. The lawsuits generally claim that J&J was aware of the risk of this side effect, but understated the risk to doctors.
It is also the latest in a series of costly legal setbacks for J&J in a slew of lawsuits alleging injuries from products and other claims. In August, an Oklahoma judge ordered the company to pay $572 million for contributing to the state's opioid-addiction crisis .
Last year, a St. Louis jury found J&J should pay $4.69 billion in damages to 22 women and their families who blamed ovarian-cancer cases on use of the company's baby powder.
J&J has denied the allegations and is seeking to appeal the baby-powder and opioid decisions. Last week, J&J said it agreed to pay $20.4 million to settle lawsuits filed by two Ohio counties alleging the company helped spark the opioid epidemic; the company didn't admit liability. [...]
Read the full article.
Read the Full Article
Tags
children's health medical safety pharmaceuticals public health